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Herpes zoster (HZ) is a viral disease characterized by a dermato-
logic and neurologic involvement caused by the reactivation of the 
latent varicella zoster virus (VZV) acquired during primary infec-
tion (varicella). HZ incidence increases with age and is related to 
waning specific cell-mediated immunity (CMI). The most frequent 
complication of HZ is post-herpetic neuralgia (PHN) charac-
terized by chronic pain lasting at least 30 days, with impact on 
patients’ quality of life. Available treatments are quite unsatisfac-
tory in reducing pain and length of the disease. The evaluation of 
the epidemiology, the debilitating complications (PHN), the sub-
optimal available treatments and the costs related to the diagno-
sis and clinical/therapeutic management of HZ patients have been 
the rationale for the search of an adequate preventive measure 
against this disease. The target of this intervention is to reduce 
the frequency and severity of HZ and related complications by 
stimulating CMI. Prevention has recently become possible with 
the live attenuated vaccine Oka/Merck, with an antigen content at 
least 10-fold higher than the antigen content of pediatric varicella 
vaccines. Clinical studies show a good level of efficacy and effec-
tiveness, particularly against the burden of illness and PHN in all 
age classes. Accordingly to the summary of the characteristics of 
the product the zoster vaccine is indicated for the prevention of 
HZ and PHN in individuals 50 years of age or older and is effec-
tive and safe in subjects with a positive history of HZ.
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Summary
Introduction
Herpes zoster (HZ) is an acute infectious disease sus-
tained by the reactivation of varicella zoster virus 
(VZV); this latter is an ubiquitous pathogen that, after 
primary infection (varicella), becomes latent in sensory 
ganglia [1].
VZV is an alpha-herpes virus characterized by a fast 
replication cycle, a rapid inter-cellular spreading and the 
ability to establish latency, mainly in dorsal root gan-
glia  [2, 3]. The virus contains a double-stranded DNA 
genome, has an icosaedric capsid (with 162 capsomers), 
a tegument and an envelope [4]. Envelope glycoproteins 
allow the virus to adhere to human cells, mainly in the 
respiratory tract; then the virus, before becoming latent, 
infects peripheral blood mononuclear cells (PBMC) and 
epidermal cells, causing the typical rash [5, 6].
VZV reservoir is exclusively human; the virus is air-
transmitted and is quite labile outside host cells  [7]. It 
could be also transmitted by skin lesions of subjects af-
fected by varicella or zoster. In about a quarter of in-
fected individuals, mainly in adulthood, latent VZV re-
activates causing HZ. About 10-30% of people infected 
by VZV will develop an episode of HZ during their life-
time; HZ incidence is particularly high in elderly and 
in immunocompromised subjects  [8]. Reactivation is 
strictly related to a decrease in the cell-mediated immu-
nity (CMI); this latter is inversely related to age. During 
reactivation, the virus replicates, causes neuronal dam-
age and inflammation, and a vesicular rash with derma-
tomal distribution. The rash typically involves the der-
matomal distribution of one single sensory nerve and, 
in immunocompetent subjects, lasts for 2-3 weeks with 
moderate to severe pain. A rate of HZ cases are associ-
ated with pain lasting some weeks to months, and even 
years. This medical case is called post-herpetic neural-
gia (PHN), and is usually defined as a pain lasting more 
than 90 days after the healing of the skin rash. PHN has 
a high impact on patients’ quality of life [9, 10].
Immunological aspects
VZV primary infection elicits innate immune response, 
characterized by IFN-α, IFN-g and IL-6 release, as well 
as humoral and cell-mediated immunity [11]. CMI plays 
an important role in limiting viral replication and avoid-
ing severe disease  [12]; humoral immune response is 
probably less relevant, as suggested by un-complicated 
varicella cases in agammaglobulinemic patients [13, 14].
However, VZV primary infection elicits a long lasting 
antibody-mediated and cell-mediated immune response. 
There is an ample consensus on the crucial role played 
by CMI in preventing VZV reactivation. Immunosenes-
cence or immunosuppression that imply a decrease of 
VZV-specific CMI are strictly related to the occurrence 
of HZ cases  [15]. An international debate is ongoing 
on the role of exogenous and endogenous boosting of 
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VZV-specific CMI; it has been suggested that exposure 
to varicella, causing an increase of specific CMI, could 
decrease the risk of VZV reactivation  [16,  17]. This 
hypothesis is supported by studies demonstrating a de-
creased risk of HZ in subjects with household or occupa-
tional exposition to varicella [18]. Other authors believe 
that endogenous booster plays a role in preventing HZ 
incidence, as an increase of HZ cases has not been dem-
onstrated in subjects surely not exposed to exogenous 
boosting [19]. Anyway, a HZ case elicits an increase of 
specific CMI, and this is probably the reason why re-
lapse of HZ is quite rare [20].
Clinical aspects
The clinical course of HZ consists of 4 phases: prodro-
mic, acute, sub-acute and chronic [21]. The prodromic 
phase usually (70-80% of cases) starts 1-5 days before 
the onset of rash  [22]; its symptoms are aspecific and 
include pruritus, burning sensations, fever, malaise and 
headache [23]. The acute phase is characterized by der-
matomal skin rash with vesicles; the duration of the rash 
is related to the age of the subject (it increases with ag-
ing) and to the dermatomes involved. Vesicles evolve 
in crusts in few days and then lesions heal. VZV can be 
transmitted during the vesicular phase; contagiousness 
halts during the crusting phase [24]. Acute pain during 
rash is related to the neurotropism of the virus [25]. Pain 
in the acute phase is described as pulsating, shooting, 
burning or piercing; it can be continuous or intermittent, 
as well as it can be associated with pruritus, tingling and/
or numbness. Many patients show allodynia, with pain 
due to a stimulus which does not normally provoke pain 
(e.g. contact of dresses on the skin) [26]; this latter may 
have an impact on quality of life and may be prognostic 
of incoming PHN [27]. Sub-acute phase usually comes 
before chronic disease (30-90 days after rash)  [27]. 
Chronic phase is characterized by PHN, with a pain 
lasting up to months and even years [26]. Most patients 
classify this pain as moderate-severe, with a pain score 
≥ 4 on a scale ranging between 0 and 10; they are usually 
treated with analgesics [28]. HZ can be severe, particu-
larly in immunocompromised subjects; disseminated 
HZ, HZ ophtalmicus, encephalitis, facial palsy, Bell’s 
palsy and Ramsay Hunt syndrome are the most common 
complications of HZ  [29]. HZ ophtalmicus implies an 
involvement of the first branch of the trigeminal nerve; 
it occurs in the 1-10% of all HZ cases [30] and it may be 
related (at least in 1/3 of cases) to the Hutchison’s sign 
(nasociliary skin lesion). This latter is prognostic of ocu-
lar inflammation and corneal sensory denervation [31]. 
A delayed contralateral hemiparesis following HZ oph-
talmicus is quite rare, but it is related to a high risk of 
neurological sequelae and to a case fatality ratio equal to 
20-25% [32, 33]. Recently, two researches, performed in 
UK, have demonstrated a higher risk of stroke, transient 
ischemic attack and myocardial infarction in subjects 
youngers than 40 years and affected by HZ; this risk is 
higher in subjects with HZ ophtalmicus [34-36].
Early diagnosis and timely therapy are essential in order 
to reduce frequency and severity of complications and to 
improve the outcome of infection. However, the thera-
peutic approach to HZ and its complications (PHN in 
particular) is quite difficult. Therapy should start as soon 
as possible (within max 72 hours from disease onset), in 
order to avoid a loss of efficacy [37]. Most of the thera-
peutic options are related to undesirable effects and al-
low to achieve only sub-optimal results. Therefore, PHN 
is difficult to prevent and to treat [38-41].
Epidemiology
Industrialized countries report a quite similar age-related 
incidence; 20-35% of subjects living in these countries 
has a HZ case during its lifetime [29]. Complications oc-
cur in 13-40% of cases [42]; 8-27% of subjects with HZ 
suffer of PHN  [43]. HZ incidence increases with age, 
being four-fold higher in subjects ≥ 70 years of age than 
in < 60 year-old subjects [44].
In the USA 0.5-1 million HZ cases are estimated each 
year, accounting for an incidence equal to 2-3/1,000/year 
in the general population [45]. Incidence is low in sub-
jects younger than 40 years of age (0.9-1.9/1,000/year); 
it increases to 2.5, 3.8, 6.1, 8.5 and 9.4 per 1,000 per year 
in subjects belonging to the age classes 40-49, 50-59, 
60-69, 70-79 and ≥ 80 years, respectively [46, 47]. The 
estimates in Europe suggest that 1.7 ± 0.1 million of new 
cases occur every year; incidence rates increase with ag-
ing also in this geographical area (2/1,000 and 10/1,000 
in < 40 and ≥ 80 year-old subjects, respectively)  [48]. 
The female/male ratio is equal to 1.4, and incidence in 
females seems to increase with aging [49]; this pattern 
of incidence could be related to the greater attitude of 
females to look for medical advice [50].
In Italy, 157,000 new cases (annual incidence: 6.3/1,000 
person-years) are estimated to occur each year; most cas-
es (76.2%) are reported by ≥ 50 year-old subjects [51]. 
Twenty point six (20.6%) and 9.2% of HZ cases have 
PHN at 3 and 6 months, respectively [52]. In the period 
1999-2005, 35,328 hospitalizations due to HZ have been 
reported (mean: 4,503/year); 62% of these hospitaliza-
tions involved subjects older than 65 years [53].
HZ and PHN have a negative impact on quality of life 
and on social life of affected people, reducing physical 
ability, implying malaise, fatigue, anorexia, weight loss, 
insomnia  [54]. Besides, symptoms (skin lesions and 
pain) together with functional and social impairment re-
lated to HZ could have, particularly in case of chronic 
disease, an impact on patients’ psychology [55, 56].
New preventive option: zoster vaccine
The burden in terms of morbidity and of short- and long-
term complications, the sub-optimal therapeutic options 
and the high costs related to HZ has allowed the search 
of a new preventive approach by vaccination. Since 
many years it has been demonstrated that live attenuated 
VZV vaccines can boost VZV-specific CMI. In particu-
lar, live attenuated varicella vaccines, with a high anti-
G. Gabutti et al.
132
gen content, elicit a significant increase of VZV-specific 
CMI in immunocompetent elderly subjects [57-61].
The zoster vaccine, developed by Merck and nowadays 
commercially available, has an antigen content higher 
than at least 19,400 PFU (Plaque-Forming Units), i.e. at 
least 10 times higher than the antigen content in pediat-
ric varicella vaccine [62]. During the last years several 
studies on efficacy, effectiveness and safety of this vac-
cine have been performed.
Noteworthy, a phase III study is ongoing to evaluate 
the efficacy, safety and immunogenicity of GSK Bio-
logicals’ candidate Herpes Zoster vaccine in adults aged 
≥ 50 years (NCT01165177 and NCT01165229).
Zoster vaccine: evaluation of efficacy
The efficacy of the new zoster vaccine has been evalu-
ated in two phase III clinical trials involving more than 
38,000 subjects ≥ 60 years of age (SPS: shingles preven-
tion study) and 22,000 subjects 50-59 years of age (ZEST: 
Zoster efficacy and safety trial), respectively [63, 64].
The SPS has allowed to collect data useful to obtain 
vaccine licensure in USA and in Europe. The SPS has 
been a multicenter, double-blinded, placebo controlled, 
randomized clinical trial, performed in the USA, enroll-
ing immunocompetent subjects ≥ 60 years of age with 
a positive anamnesis of varicella or residing for at least 
30 years in a VZV-endemic area. The exclusion criteria 
were positive anamnesis of zoster, allergy to any vacci-
nal component, immunosuppression or any other condi-
tion that could interfere with the evaluation of results. 
Randomized subjects received one dose (0.5 ml) of the 
zoster vaccine (n = 19,270) or of placebo (n = 19,276). 
The mean age of both groups was equal to 69 years 
(46% and 6.5% of subjects were ≥ 70 and ≥ 80 year old, 
respectively). The follow up period lasted a mean of 3.1 
years (range 1 day-4.9 years).
The primary end point of the study was the evaluation of 
safety and efficacy of the vaccine. In particular, vaccine 
efficacy was evaluated as the reduction of the burden 
of illness (BOI). This end point includes incidence, se-
verity and duration of acute and chronic pain related to 
HZ during a follow-up period of at least 6 months. The 
secondary end point of the study was vaccine efficacy 
against the incidence of PHN (pain with a ≥ 3 score on 
a scale ranging from 0 to 10 and lasting at least 90 days 
after the onset of rash). Pain and discomfort have been 
evaluated and measured by a questionnaire filled in by 
patients after the onset of HZ (Brief Pain Zoster Inven-
tory). A score ≥ 3 has been considered clinically signifi-
cant, as it is related to a relevant decrease of normal dai-
ly activities [65, 66]. Another secondary end point was 
the efficacy against the incidence of HZ. More than 95% 
of enrolled subjects have completed the study; a total of 
957 HZ cases occurred, 315 among immunized subjects 
and 642 in subjects receiving placebo. Concerning the 
primary end point, the efficacy against BOI was equal to 
61.1% (95%CI: 51.1-69.1).
During the study, 107 cases of PHN have been regis-
tered, 27 in immunized subjects and 80 in the placebo 
group. The efficacy against PHN has been equal to 
66.5% (95%CI:  47.5-79.2); the efficacy against PHN 
stratified by age has been 65.7% (95%CI: 20.4-86.7) and 
66.8% (95%CI: 43.3-81.3) in the age groups 60-69 and 
≥  70 years, respectively. The level of efficacy against 
PHN increased accordingly to the definition of the dura-
tion of the chronic pain (58.9% and 72.9% for PHN de-
fined as pain persisting 30 days and 182 days after rash 
onset, respectively).
The study has also demonstrated an efficacy against HZ 
equal to 51.3% (95%CI: 44.2- 57.6); the level of effica-
cy decreased in older subjects (63.9% and 18% in 60-69 
and ≥ 80 year-old subjects).
The level of efficacy against HZ decreased in older 
subjects, while the efficacy against PHN and BOI was 
not related to the age group considered. HZ occurring 
in immunized subjects lasted for a shorter time than 
cases registered in the placebo group (21 vs. 24 days; 
p  =  0.03)  [63]. Another efficacy study, called ZEST 
(Zoster Efficacy and Safety Trial), was performed in 
North America and in Europe in the period October 
2007-January 2010. It was a double-blinded, placebo 
controlled, randomized clinical trial that involved sub-
jects 50-59 year-old subjects with a positive anamnesis 
of varicella or living for at least 30 years in a VZV-en-
demic area [64]. Exclusion criteria were quite similar to 
the ones adopted in the SPS trial; a total of 22,439 were 
enrolled to receive a dose of zoster vaccine (n = 11,211) 
or placebo (n = 11,228). The mean follow-up period was 
1.3 years (range 0 days-2 years).
The end point of the trial was to assesses vaccine efficacy, 
safety and tolerability in immunized group compared to 
the placebo one. Efficacy against HZ was 69.8% (95%CI: 
54.1-80.6); 30 and 99 HZ cases were registered in the im-
munized and in the placebo group, respectively (p < 0.001).
The efficacy of zoster vaccine in the ZEST study in 
the age group 50-59 years resulted similar to the one 
observed in the SPS trial in the age group 60-69 years 
(63.9%), and higher than in subjects ≥ 70 years of age 
(37.6%). The results obtained in the ZEST study were 
in line with those obtained during the SPS trial [63, 64]; 
the higher efficacy against HZ observed in the ZEST 
study is probably related to a better immune response of 
younger subjects [64].
The duration of efficacy has been evaluated as well in 2 
persistence substudies: short-term persistence substudy 
(STPS) and long-term persistence substudy (LTPS).
The STPS started in October 2005; in this open-label 
study zoster vaccine was offered to subjects previously 
enrolled in the SPS placebo group. The follow-up in 
this substudy involved zoster vaccine recipients in the 
SPS as well. A total of 14,270 subjects were enrolled 
in the STPS substudy: 7,320 subjects were zoster vac-
cine recipients and 6,950 were placebo recipients in the 
SPS trial. These latter were offered one dose of zoster 
vaccine; the mean age was equal to 73.3 years and the 
follow-up lasted for a mean of 1.2 years (range 1 day-2.2 
years). Efficacy in the STPS has been evaluated against 
the 3 end points already used in the SPS trial: BOI, PHN 
and HZ incidence. In the STPS the efficacy has been 
assessed on data basically collected 4-7 years after the 
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immunization performed in the SPS; 84 and 95 HZ cases 
occurred in the group of immunized subjects and in the 
placebo group, respectively.
The estimated efficacy in the STPS has been the fol-
lowing: 50.1% against BOI (95%CI: 14.1-71); 60.1% 
against PHN (95%CI: -9.8-86.7); 39.6% against HZ 
(95%CI: 18.2%-55.5).
Taking into account the combined results of SPS and 
STPS, vaccine zoster showed an efficacy equal to 58.6% 
(95%CI: 48.6-66.6), 64.9% (95%CI: 47.4-77.0) and 
48.7% (95%CI: 42.0-54.7) against BOI, PHN and HZ, 
respectively. STPS vaccine efficacy for each end point 
was lower than in the SPS; anyway, a persistence of vac-
cine efficacy was demonstrated through year 5 after im-
munization [67].
The long-term persistence substudy (LTPS) evaluated 
6,867 subjects that had been immunized during the SPS 
and the STPS [67, 68]; for this reason a control group was 
not available. The mean age at enrollment was equal to 
74.5 years; the mean follow-up was 3.9 years (range 1 
week-4.75 years). In the LTPS efficacy has been evaluated 
7-10 years after immunization. The HZ incidence during 
the LTPS was 10.3/1,000 person-years and the efficacy 
was: 37% against BOI (95%CI: 27-46), 35% against PHN 
(95%CI: 9-56) and 21% against HZ (95%CI: 11-30).
Zoster vaccine: evaluation of effectiveness
Clinical trials (SPS, ZEST, STPS, LTPS) have demonstrat-
ed the efficacy and the safety of the new zoster vaccine. It is 
important to demonstrate that similar results are obtained in 
the “real life”; for this reason post-marketing effectiveness 
studies are relevant and have been performed.
In the period January 2007-December 2009, Tseng et al. 
have enrolled 2 groups of subjects included in the Kai-
ser Permanente Southern California health plan; the first 
one accounted for 75,761 subjects who received zoster 
vaccine, the second one accounted for 227,283 unimmu-
nized subjects. The mean duration of the follow up was 
equal to 1.56 and 1.72 years for vaccinated and unvac-
cinated cohorts, respectively; during this period, 5,434 
HZ cases occurred with an incidence equal to 13/1,000 
person-years (95%CI: 12.6-13.3) and 6.4/1,000 person-
years (95%CI: 5.9-6.8) in unimmunized and immunized 
subjects, respectively.
HZ incidence in unimmunized subjects resulted higher in 
older subjects (≥ 80 vs. 60-64 year old subjects, Hazard 
ratio (HR) 1.45, 95%CI: 1.3-1.63), lower in males (HR 
0.75, 95%CI: 0.7-0.79), and in black people (HR 0.69, 
95%CI: 0.62-0.76). HZ incidence was higher, even if not 
statistically significant, in unvaccinated subjects affected 
by lung (HR 1.34, 95%CI: 0.95-1.13), kidney (HR1.04, 
95%CI: 0.95-1.13) and cardiac (HR 1.06, 95%CI: 0.97-
1.16) diseases. Immunization was positively related to a 
decrease of the risk of HZ (HR 0.45, 95%CI: 0.42-0.48), 
HZ ophtalmicus (HR 0.37, 95%CI:  0.23-0.61), hospi-
talizations due to HZ (HR 0.35, 95%CI: 0.24-0.51). As 
a whole, immunization allowed to achieve a 55% reduc-
tion of the HZ incidence; this result is consistent with 
the one obtained during the SPS (51%). However, in this 
effectiveness study the positive impact of immunization 
did not change considering different age classes, sup-
porting the recommendation to provide HZ vaccine even 
to oldest subjects [69].
Zhang et al. have evaluated the effectiveness of zoster 
vaccine in patients affected by immune-mediated diseas-
es. The study, performed in the period January 2006-De-
cember 2009, involved 463,541 insured by Medicare 
and affected by rheumatoid arthritis (292,169), psoriatic 
arthritis (11,030), psoriasis (89,565), ankylosing spon-
dylitis (4,026), inflammatory bowel disease (66,751). 
The inclusion criteria included: age ≥ 60 years, diagno-
sis of at least one of the previously mentioned diseases, 
inclusion in the Medicare since at least 6 months. Zos-
ter vaccine was provided to 18,683 subjects (72.3% fe-
males, 86.3 white); the mean age of enrolled people was 
74 years.
Eleven HZ cases occurred in vaccinated subjects, 
with an incidence rate of 7.8 cases/1,000 person-years 
(95%CI: 3.7-16.5). No varicella or HZ cases were reg-
istered in patients in treatment with biologics or with 
anti-TNF during the 42 days following immunization. 
After controlling for demographic data, type of immune-
mediated disease, the accesses to health care, the use of 
biologic or nonbiologic disease-modifying antireumath-
ic drugs (DMARDs) or oral glucocorticoids, the hazard 
ratio (HR) of HZ related to immunization resulted equal 
to 0.61 (95%CI:  0.52-0.71) and the vaccine effective-
ness equal to 39%. This study has demonstrated that zos-
ter vaccine is not related to an increased risk of varicella 
or HZ in patients under biologic treatment [70].
More recently, Langan et  al. have studied a cohort of 
766,330 subjects older than 65 years, enrolled in the pe-
riod January 2006-December 2009, and involved in the 
Medicare programs A (covers inpatients care), B (covers 
physician services and facility costs) since at least 12 
months and registered since at least 6 months in program 
D (drug benefit). As a whole, 29,758 subjects received 
zoster vaccine; 4,469 were immunosuppressed at the 
time of zoster immunization.
As a whole, 154 HZ cases occurred in 28,291 person-
years of follow up in vaccinated subjects compared to 
12,958 HZ cases in 1,291,829 person-years of follow 
up in unvaccinated subjects; the HZ incidence rate was 
equal to 5.4/1,000 person-year (95%CI: 4.6-6.4) and to 
10/1,000 person-year (95%CI:  9.8-10.2) in vaccinated 
and unimmunized subjects, respectively.
Vaccine effectiveness against HZ in vaccinated subjects 
has been equal to 0.48 (95%CI: 0.39-0.56)
In immunocompromised subjects the vaccine effective-
ness has been equal to 0.37 (95%CI: 0.06-0.58) (24 HZ 
cases in 1,981 immunosuppressed patients). The occur-
rence of PHN (30 days after HZ onset) has been equal 
to 16 PHN case in 71,457 immunized subjects and 1,665 
PHN cases in 2,563,404 cases in unimmunized subjects; 
the effectiveness against PHN has been equal to 0.62 
(95%CI: 0.37-0.77) and to 0.59 (95%CI: 0,21-0.79) at 
30 and 90 days, respectively. Langan et al. have dem-
onstrated a zoster vaccine effectiveness equal to 48%, 
62% and 59% against HZ, PHN at 30 days and PHN at 
90 days, respectively. The same study has confirmed the 
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zoster vaccine effectiveness in routine clinical use, even 
in immunosuppressed individuals [71].
A long-term effectiveness study has been planned in 
subjects ≥ 50 years of age included in the Kaiser Per-
manente Northen California health plan. The target is to 
immunize 15,000 subjects; a preliminary phase started 
in 2012, is already ongoing and two ad interim analysis 
are planned at the end of 2016 and 2020; the study will 
end in 2024 [68, 72].
Zoster vaccine: evaluation of safety
The studies SPS and ZEST has allowed to evaluated safe-
ty and tolerability of the new zoster vaccine. In detail, 
the SPS trial demonstrated an excellent tolerability and 
safety profile [63]. In this trial each enrolling site closely 
monitored adverse events in a subset of subjects (safety 
substudy). As a whole, the incidence of hospitalizations 
and deaths has been quite similar during the follow-up 
of both groups of subjects involved in the study. Dur-
ing the 42 days following immunization, a rash (usually 
mild) at the site of injection has been registered more 
frequently in immunized subjects than in those receiv-
ing placebo. Seven and 24 HZ cases has been registered 
in immunized and placebo-receiving subjects during the 
first 42 days after immunization. The Oka/Merck vac-
cinal strain has not been detected in any sample.
Five severe adverse events (SAEs) have been reported; 
only 2 have been observed in the immunized group.
The safety substudy pointed out a greater frequency of 
adverse events (AEs) involving the site of injection in 
the vaccine group than in the placebo; in immunized 
subjects the most frequent AEs have been erythema 
(35.8%), pain or tenderness (34.5%), swelling (26.2%), 
and pruritus (7.1%).
SAEs occurring during the first 42 days after immuniza-
tion have been significantly higher in the vaccine group 
than in the placebo one (1.9% vs. 1.3%, p = 0.03). No 
significant differences in SAEs distribution accordingly 
to site or type of event has been demonstrated. No hos-
pitalization was related to immunization [63].
The ZEST study confirmed the safety profile of zoster 
vaccine. The rate of at least one AEs was higher in im-
munized subjects than in those receiving placebo (73% 
vs. 42%), most of AEs were at the injection site. Few 
(0.7%) AEs have been reported as grade 3. Systemic 
AEs were reported in 35% of immunized subjects; 6.7% 
of these have been related to the vaccine. During the 
ZEST study the AEs incidence in immunized subjects 
has resulted higher than the one observed in the SPS 
study (63.9% vs. 48.3%); this fact could be possibly 
explained with a higher local reactogenicity in younger 
subjects [73]. The rate of subjects with SAEs during the 
first 42 days following immunization has been similar 
in immunized and in placebo group (0.6% vs. 0.5%). An 
anaphylactic reaction has been reported 15 minutes after 
vaccine administration with no sequelae. The molecu-
lar analysis of biological samples (n = 47) belonging to 
subjects with HZ-like rashes (n = 34) and varicella-like 
rashes (n = 124) identified wild-type virus in 11 cases; 
no Oka/Merck strain has been detected [64].
The safety profile of zoster vaccine has also been as-
sessed in a study involving almost 12,000 subjects ≥ 60 
years of age (5,983 immunized and 5,997 receiving pla-
cebo). During the first 42 days of follow up, a SAE was 
reported by 1.4% and 1.12% of immunized and placebo-
receiving subjects, respectively (relative risk RR 1.26; 
95%CI:  0.91-1.73; not statistically significant). Dur-
ing the follow up at 182 days, 5.7% (n = 340) and 5% 
(n  =  300) subjects, immunized and placebo-receiving 
respectively, reported a SAE; the RR in this analysis 
was equal to 1.13 (95%CI:  0.98-1.32; not statistically 
significant). In conclusion, this study has demonstrated 
that the incidence of SAEs in the period 1-42 days and 
at 6 months was not statistically different comparing im-
munized and placebo-receiving subjects [74].
Zoster vaccine resulted well tolerated in a clinical trial 
involving subjects > 60 years of age on chronic/mainte-
nance corticosteroids (5-20 mg of prednisone or equiva-
lent daily/dose) for at least 2 week before enrollment and 
for > 6 weeks after immunization [62].
Two studies [75, 76] have shown that zoster vaccine is 
safe in subjects with a recent history of documented HZ 
in accordance to recommendations by CDC Advisory 
Committee on immunization practices already estab-
lished in 2008 [77].
The good safety and tolerability profile of zoster vac-
cine has been confirmed in all effectiveness studies per-
formed after licensure and commercial availability of 
the product. Generally, the most frequent AEs reported 
have been injection site reactions (redness, swelling and 
pain) (≥ 1/10) and headache (from ≥ 1/100 to < 1/10). No 
cases of secondary transmission of vaccinal strain have 
been reported; no age-related specific safety issues have 
been demonstrated.
Recently, a HZ case caused by VZV vaccine strain has 
been documented in an immunocompetent recipient 
of zoster vaccine  [78]. The efficacy, effectiveness and 
safety profile of zoster vaccine has recently been con-
firmed in an European Health Technology pilot assess-
ment [79].
Conclusions
The evaluation of the epidemiology, the frequent and de-
bilitating complications (PHN), the sub-optimal available 
treatments and the costs related to the diagnosis and clini-
cal/therapeutic management of HZ patients have been the 
rationale for the search of an adequate preventive measure 
against this important disease. The target of this specific 
intervention is to reduce the frequency and severity of 
HZ and related complications by stimulating CMI. High-
antigen content vaccines elicit an effective CMI response, 
also in elderly subjects. Prevention has recently become 
possible with the live attenuated vaccine Oka/Merck, with 
an antigen content at least 10-fold higher than the antigen 
content of pediatric varicella vaccines. Clinical studies 
show a good level of efficacy and effectiveness, partic-
ularly against the burden of illness and PHN in all age 
classes. Protection seems to be long lasting and vaccine 
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safety matches registration requirements. Accordingly 
to the summary of the characteristics of the product the 
zoster vaccine is indicated for the prevention of HZ and 
HZ-related PHN of individuals 50 years of age or older 
and is effective and safe in subjects with a positive his-
tory of HZ. The evaluation of all the above mentioned 
points has already allowed some countries to recommend 
the use of zoster vaccine (e.g. USA, Canada, Austria, UK, 
Germany/Saxony, Sweden, Greece, France).
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